~~<i id='698BB542A7'><strike id='698BB542A7'><tt id='698BB542A7'><pre id='698BB542A7'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

leisure time

fashion

author：leisure time 2025-09-29 16:34:36 - browse：7116

Roche’s announcement Monday that it would pay $310 million for rights to a hypertension treatment, zilebesiran, invented by the biotech firm Alnylam is evidence of a renewed interest on the part of large pharmaceutical companies for treatments for cardiovascular disease.

If things go well, Roche could pay Alnylam up to $2.8 billion in total.

Heart drugs were once the most lucrative category of pharmaceuticals, but they have been eclipsed by treatments for cancer and other diseases as drug firms have struggled to one-up existing treatments for high blood pressure and high cholesterol that are now available as cheap generics.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Cancer drug shortages should be causing more outrage
Next article： Mindstrong's demise and the future of mental health care

hotspot

knowledge

entertainment

leisure time

knowledge

AdobeApanelofindependentadviserstotheFoodandDrugAdministrationvotedoverwhelminglyagainstapolarizingp

WSS

Senator probes 340B programs at Cleveland Clinic, Bon Secours

After a drawn out lobbying fight, ARPA

WHO recommends dropping component of many flu vaccines

Kaiser Permanente unions announce official strike date

Mindstrong's demise and the future of mental health care

Medicare drug price negotiation program allowed for now

leisure time

fashion

hotspot

Tori Bowie and the unacceptable rates of Black maternal death

How the Dana

Wildfire smoke exposes gaps in outdoor worker protections

Senate panel eyes new effort on drug shortages

After affirmative action ruling, medical educators look to 'holistic review'

Medicare drug price negotiation program allowed for now

Activists slam private health insurers over coverage restrictions

Medicare drug price negotiation program allowed for now

Moonlake's readout produced a cash windfall. Risks remain

Stroke deaths set to near 10 million globally by 2050

knowledge

Researchers use wearables data and AI to predict preterm birth risk

What to expect at HLTH 2023, the health care industry conference

Data show record exodus of life scientists from academia

Mindstrong's demise and the future of mental health care

Why Charlie Gard's case is so disturbing to Americans

Sudafed saga points to U.S. issues with evaluating older drugs

entertainment

leisure time

leisure time

knowledge